Sugi Predict

Sugi Predict / Compounds / SCHEMBL9923808

SCHEMBL9923808

SCHEMBL9923808

CC1COc2cccc(Oc3ccc(NC(=O)C(C)(C)NC(=O)OC(C)(C)C)cn3)c2C1

nearest known ligand 0.34

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 11/20 0.34
▸ KCNH2 Q12809 9/20 0.34
▸ SCN5A Q14524 9/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ MAPT P10636 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ HTR2C P28335 5/20 0.34
▸ HTR2B P41595 2/20 0.34
▸ MTNR1A P48039 1/20 0.33
▸ MTNR1B P49286 1/20 0.33
▸ PKM P14618 1/20 0.33
▸ GALR3 O60755 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ HTR2A P28223 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29438010 1.00 SCN9A (0.34) SCN9AKCNH2SCN5ARAB9AMAPT
SCHEMBL17188989 0.92 MEN1 (0.34) SCN9AKCNH2SCN5ARAB9AMAPT
SCHEMBL15303321 0.90 MTNR1A (0.35) SCN9AKCNH2SCN5ARAB9AMAPT
SCHEMBL20921380 0.90 MTNR1A (0.35) SCN9AKCNH2SCN5ARAB9AMAPT
SCHEMBL9924047 0.88 MAPT (0.37) SCN9AKCNH2SCN5ARAB9AMAPT
SCHEMBL9904583 0.84 MTNR1A (0.36) SCN9AKCNH2SCN5ARAB9AMAPT
SCHEMBL21116930 0.84 MTNR1A (0.36) SCN9AKCNH2SCN5ARAB9AMAPT
SCHEMBL9901280 0.82 PKM (0.34) SCN9AKCNH2SCN5ARAB9AMAPT
SCHEMBL9900825 0.82 RAB9A (0.33) RAB9AMAPTHTTHTR2CHTR2B
SCHEMBL15308381 0.81 RAB9A (0.35) RAB9AMAPTHTTHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2023-02-21 — — US disclosed
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2022-02-24 — — US disclosed
US-11197859-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2021-12-14 — — US disclosed
US-20200360379-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2020-11-19 — — US disclosed
US-20190192516-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2019-06-27 — — US disclosed
US-10265316-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUCTICS LIMITED (GB) 2019-04-23 — — US disclosed
US-20170273981-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2017-09-28 — — US disclosed
US-20170273981-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2017-09-28 — — US disclosed
US-20160251340-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2016-09-01 — — US disclosed
US-20160251340-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2016-09-01 — — US disclosed
US-9346790-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2016-05-24 — — US disclosed
US-9346790-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2016-05-24 — — US disclosed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 — — US disclosed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 — — US disclosed
WO-2012076877-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2012-06-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190192516-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNN3, KCND3, KCNA3 SCN9A 92/4885KCNH2 14/4885SCN5A 68/4885
US-20160251340-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNA3, KCND3, KCNN3 SCN9A 97/4885KCNH2 10/4885SCN5A 63/4885
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors KCNN3, KCND3, KCNA3 SCN9A 92/4885KCNH2 14/4885SCN5A 68/4885
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNN3, KCND3, KCNA3 SCN9A 92/4885KCNH2 14/4885SCN5A 68/4885
US-20200360379-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNN3, KCND3, KCNA3 SCN9A 92/4885KCNH2 14/4885SCN5A 68/4885
US-20170273981-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNA3, KCND3, KCNN3 SCN9A 97/4885KCNH2 10/4885SCN5A 63/4885
US-10265316-B2 Hydantoin derivatives useful as Kv3 inhibitors KCNA3, KCND3, KCNN3 SCN9A 97/4885KCNH2 10/4885SCN5A 63/4885
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNA3, KCND3, KCNN3 SCN9A 97/4885KCNH2 10/4885SCN5A 63/4885
US-11197859-B2 Hydantoin derivatives useful as Kv3 inhibitors KCNN3, KCND3, KCNA3 SCN9A 92/4885KCNH2 14/4885SCN5A 68/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.